Mode
Text Size
Log in / Sign up

AI nomogram predicts malignancy risk in surgically resected pulmonary nodules ≤3 cmAI tool predicts cancer risk in lung nodules removed for surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider using this AI nomogram for preoperative surgical decision support in malignancy-enriched cohorts pending external validation.

This retrospective cohort study involved 951 consecutive patients who underwent surgical resection for pulmonary nodules (PNs) ≤3 cm. The setting was a malignancy-enriched preoperative surgical environment. The intervention was an AI-assisted clinico-quantitative imaging nomogram, a multivariable logistic regression model combining automatically extracted quantitative imaging features with clinical data and inflammatory markers. No comparator was reported as the study focused on internal validation of this specific tool.

The primary outcome was preoperative malignancy risk. Secondary outcomes included discrimination (AUC), calibration (mean absolute error), and net clinical benefit. The model achieved an AUC of 0.836 (95% CI 0.804–0.869) for discrimination. Calibration was assessed with a mean absolute error of 0.015. Malignancy rates by risk strata were lower-risk: 43.3%, intermediate-risk: 86.7%, and higher-risk: 95.0%. Safety data, including adverse events or discontinuations, were not reported.

Key limitations include the restriction of the cohort to surgically resected nodules and the malignancy-enriched nature of the preoperative setting. The model was derived in a surgically selected cohort, meaning risk estimates should be interpreted within this specific context. External validation and recalibration in independent, unselected cohorts are required before broader implementation. Consequently, the tool is best interpreted as a support for preoperative surgical decision-making rather than for screening or incidental pulmonary nodule populations.

This study evaluated an AI-assisted tool that helps doctors estimate the risk of cancer in lung nodules. The research team analyzed data from 951 patients who had these nodules surgically removed. The tool used a mathematical model that combined automatically extracted imaging features with clinical data and inflammatory markers to predict whether the nodule was malignant.

The analysis showed the tool had good accuracy, with a discrimination score of 0.836. When grouped by risk, the tool identified that lower-risk nodules had a 43.3% chance of being cancer, while higher-risk nodules had a 95.0% chance. The model performed well in this specific group of patients who were already undergoing surgery.

It is important to note that this study was limited to a group of patients selected specifically for surgery. The researchers warn that these results should not be used for screening or for nodules found incidentally in people who are not having surgery. Further testing in broader, independent groups of patients is required before this tool can be widely used outside of surgical settings.

What this means for you:
This AI tool showed promise for surgical patients but needs more testing before general use.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
To develop and internally validate an artificial intelligence (AI)–assisted clinico–quantitative imaging prediction model that combines automatically extracted quantitative imaging features with clinical data to preoperatively assess individualized malignancy risk in solid and part-solid pulmonary nodules (PNs) measuring ≤ 3 cm. This retrospective study analyzed data from 951 consecutive patients who underwent surgical resection for PNs ≤ 3 cm (210 benign, 741 malignant). Quantitative CT features, including nodule size, minimum and maximum computed tomography attenuation, consolidation-to-tumor ratio, and nodule type, were automatically measured using InferRead CT Lung AI software (Infervision, Beijing, China; version 4.0). These AI-assisted quantitative measurements were evaluated together with clinical variables and inflammatory markers as candidate predictors. The final prediction model was a multivariable logistic regression model, with predictor selection performed in the full cohort before internal bootstrap validation. Model performance was assessed using 1,000 bootstrap resamples, with discrimination quantified by the area under the receiver operating characteristic curve (AUC), calibration assessed by calibration plots, slope, intercept, and mean absolute error, and clinical utility evaluated using decision curve analysis. The final AI-assisted model demonstrated strong discrimination, with an AUC of 0.836 (95% confidence interval [CI], 0.804–0.869), and excellent calibration, with a mean absolute error of 0.015. Decision curve analysis indicated a meaningful net clinical benefit across threshold probabilities of 0.10–0.45. Risk stratification based on quartiles of predicted probability categorized patients into lower-, intermediate-, and higher-risk strata, with observed malignancy rates of 43.3%, 86.7%, and 95.0%, respectively, in this surgically managed cohort. The interactive calculator is publicly accessible at https://ruanyingding.shinyapps.io/myshinyapp/. Because the study cohort was restricted to surgically resected nodules, these risk estimates should be interpreted within a malignancy-enriched preoperative surgical setting. An AI-assisted clinico–quantitative imaging nomogram was developed and internally validated to support individualized preoperative malignancy risk assessment for indeterminate PNs ≤ 3 cm. Because the model was derived in a surgically selected, malignancy-enriched cohort, it is best interpreted as a tool for preoperative surgical decision support rather than for screening or incidental pulmonary nodule populations. External validation and, if necessary, recalibration in independent unselected cohorts are required before broader implementation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.